Colaci Carla Stefania, Mendizabal Manuel, Bessone Fernando
Hepatology and Liver Transplant Unit, Hospital Universitario Austral, Pilar, Buenos Aires, Argentina.
Latin American Liver Research Educational and Awareness Network (LALREAN), Pilar, Buenos Aires, Argentina.
Curr Drug Saf. 2019;14(2):94-101. doi: 10.2174/1574886314666190215115434.
Idiosyncratic Drug Induced Liver Injury (DILI) is a rare adverse event to drugs that occasionally leads to severe liver damage, being one of the leading causes of Acute Liver Failure (ALF) in developed countries. DILI is largely a diagnosis of exclusion.
Careful history of drug taking and ruling out other competing etiologies is mandatory given that DILI can present with an extremely variable phenotype. Several prognostic scores have been developed to promptly identify patients with potential risk of developing ALF. New biomarkers to diagnose and predict DILI evolution are under study and hopefully we will benefit from these novel tools in the near future.
特异质性药物性肝损伤（DILI）是一种罕见的药物不良事件，偶尔会导致严重肝损伤，是发达国家急性肝衰竭（ALF）的主要原因之一。DILI很大程度上是一种排除性诊断。
鉴于DILI可表现出极其多样的表型，详细的用药史及排除其他可能病因至关重要。已开发出多种预后评分系统以迅速识别有发生ALF潜在风险的患者。用于诊断和预测DILI进展的新型生物标志物正在研究中，有望在不久的将来从这些新工具中获益。
